Abstract:The pharmaceutical industry remains solely reliant on synthetic chemistry methodology to prepare compounds for small-molecule drug discovery programmes. The importance of the physicochemical properties of these molecules in determining their success in drug development is now well understood but we present here data suggesting that much synthetic methodology is unintentionally predisposed to producing molecules with poorer drug-like properties. This bias may have ramifications to the early hit- and lead-findin… Show more
“…Applying both filters showed a surprising number of compounds picked up by only a single set of the filters. The merging of the Pfizer and Wyeth screening file gave us the opportunity to revisit the existing filter sets, to combine the experiences from both companies, and incorporate also new findings of structural filters from the literature, [40][41][42][43][44][45][46][47][48] in addition to the creation of a small number of new proprietary filters to remove for example, compounds with very low feature content (no heteroatoms and low structural complexity) and compounds with multiple unattractive features, such as several nitro groups. 48 This knowledge integration resulted in the generation of a combined set of around 540 molecular filters, 55 which were applied to eliminate compounds with structural flaws ahead of the redundancy reduction.…”
“…In parallel, surveying the recent literature describing structural filters allowed us to include additional substructure filters. [40][41][42][43][44][45][46][47][48] Overall, around 140 filters were newly created and combined with the existing filter set, resulting in 540 unique substructure queries.…”
High Throughput Screening (HTS) is a successful strategy for finding hits and leads that have the opportunity to be converted into drugs. In this paper we highlight novel computational methods used to select compounds to build a new screening file at Pfizer and the analytical methods we used to assess their quality. We also introduce the novel concept of molecular redundancy to help decide on the density of compounds required in any region of chemical space in order to be confident of running successful HTS campaigns.
“…Applying both filters showed a surprising number of compounds picked up by only a single set of the filters. The merging of the Pfizer and Wyeth screening file gave us the opportunity to revisit the existing filter sets, to combine the experiences from both companies, and incorporate also new findings of structural filters from the literature, [40][41][42][43][44][45][46][47][48] in addition to the creation of a small number of new proprietary filters to remove for example, compounds with very low feature content (no heteroatoms and low structural complexity) and compounds with multiple unattractive features, such as several nitro groups. 48 This knowledge integration resulted in the generation of a combined set of around 540 molecular filters, 55 which were applied to eliminate compounds with structural flaws ahead of the redundancy reduction.…”
“…In parallel, surveying the recent literature describing structural filters allowed us to include additional substructure filters. [40][41][42][43][44][45][46][47][48] Overall, around 140 filters were newly created and combined with the existing filter set, resulting in 540 unique substructure queries.…”
High Throughput Screening (HTS) is a successful strategy for finding hits and leads that have the opportunity to be converted into drugs. In this paper we highlight novel computational methods used to select compounds to build a new screening file at Pfizer and the analytical methods we used to assess their quality. We also introduce the novel concept of molecular redundancy to help decide on the density of compounds required in any region of chemical space in order to be confident of running successful HTS campaigns.
“…Instant JChem was used for the prediction of the physico-chemical properties of the compounds. Conformational restriction provided by the saturated heteroaliphatic ring of 4 and an improved hydrophilicity are valuable features in leadoriented synthesis in medicinal chemistry [27,28]. …”
A convenient four-step approach to the synthesis of (S)-4-alkyl-2-(pyrrolidin-2-yl)oxazoles starting from l-Boc-proline inspired by naturally occurring oxazolecontaining peptidomimetics is described. The key step is the cyclization of 1-Boc-N-(1-oxoalkan-2-yl)pyrrolidine-2-carboxamides -aldehyde intermediates which demonstrate low to moderate stability -under Appel reaction conditions. This method furnishes the target compounds with more than 98% ee and in a 17-51% overall yield and has been used at up to a 45-g scale.
“…1 The molecular properties of clinical candidates [2][3][4][5] -particularly molecular size and lipophilicity 5 are strongly linked to the probability of successful negotiation of the development process. Optimisation almost inevitably leads to increases in both molecular weight and lipophilicity, making it essential to control the properties of lead compounds.…”
Section: Introductionmentioning
confidence: 99%
“…molecules that would be good starting points for lead optimisation -have recently been articulated. 1 Sourcing large numbers of lead-like small molecules is a major challenge in maintaining large, high quality screening collections. 1 The vast majority of commercially-available screening compounds -as well as compounds reported in the synthetic chemistry literature -do not have lead-like properties.…”
A modular synthetic approach is described in which combinations of cyclic sulfamidate and hydroxy sulfonamide building blocks may be converted into piperazine, 1,4-diazepine and 1,5-diazocane scaffolds.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.